Literature DB >> 6276504

Development of serum and intestinal antibody response to rotavirus after naturally acquired rotavirus infection in man.

M Riepenhoff-Talty, S Bogger-Goren, P Li, P J Carmody, H J Barrett, P L Ogra.   

Abstract

The temporal characteristics of the response of rotavirus specific IgM, IgG, IgA in serum and secretory antibody in feces to rotavirus were studied in 77 hospitalized patients with rotavirus induced gastroenteritis. The response in serum was characterized by the sequential appearance of rotavirus specific IgM, IgG, and IgA antibody. The IgM antibody appeared to be higher in the acute phase of the disease and was subsequently replaced by the IgG and IgA antibodies. However, the titers of IgG rotavirus antibody in convalescent specimens of serum were found to be statistically significantly lower in patients with severe or prolonged rotavirus infection than in specimens from subjects with mild or moderate disease. Most fecal specimens collected during both the acute and convalescent phase of illness contained virus specific secretory IgA. Higher concentrations of antibody were measured in convalescent samples from patients with prolonged diarrhea and virus shedding. These observations suggest a possible relationship between the severity of rotavirus infection and the nature of systemic and secretory antibody response.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6276504     DOI: 10.1002/jmv.1890080309

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  19 in total

Review 1.  Defense system in the biliary tract against bacterial infection.

Authors:  J Y Sung; J W Costerton; E A Shaffer
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

2.  Demonstration of a lack of synergistic effect of rotavirus with other diarrheal pathogens on severity of diarrhea in children.

Authors:  L E Unicomb; S M Faruque; M A Malek; A S Faruque; M J Albert
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 3.  Human viral gastroenteritis.

Authors:  G Cukor; N R Blacklow
Journal:  Microbiol Rev       Date:  1984-06

4.  Persistent rotavirus infection in mice with severe combined immunodeficiency.

Authors:  M Riepenhoff-Talty; T Dharakul; E Kowalski; S Michalak; P L Ogra
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

5.  The effects of infant feeding on rotavirus-induced gastroenteritis: a prospective study.

Authors:  L C Duffy; T E Byers; M Riepenhoff-Talty; L J La Scolea; M Zielezny; P L Ogra
Journal:  Am J Public Health       Date:  1986-03       Impact factor: 9.308

6.  Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates.

Authors:  K Midthun; L Z Pang; J Flores; A Z Kapikian
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

7.  Patients with enteric adenovirus gastroenteritis admitted to an Australian pediatric teaching hospital from 1981 to 1992.

Authors:  K Grimwood; R Carzino; G L Barnes; R F Bishop
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

8.  Serum IgA immune response to individual rotavirus polypeptides in young children with rotavirus infection.

Authors:  K Johansen; L Granqvist; K Karlén; G Stintzing; I Uhnoo; L Svensson
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Immunization with baculovirus-expressed recombinant rotavirus proteins VP1, VP4, VP6, and VP7 induces CD8+ T lymphocytes that mediate clearance of chronic rotavirus infection in SCID mice.

Authors:  T Dharakul; M Labbe; J Cohen; A R Bellamy; J E Street; E R Mackow; L Fiore; L Rott; H B Greenberg
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

10.  Serologic and mucosal immune response to rotavirus infection in the rabbit model.

Authors:  M E Conner; M A Gilger; M K Estes; D Y Graham
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.